%0 Journal Article
%A Bukkems, Vera
%A Necsoi, Coca
%A Tenorio, Carmen Hidalgo
%A Garcia, Coral
%A Rockstroh, Jürgen
%A Schwarze-Zander, Caroline
%A Lambert, John S
%A Burger, David
%A Konopnicki, Deborah
%A Colbers, Angela
%T Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
%D 2020
%U http://hdl.handle.net/10668/15427
%X This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.
%K HIV
%K cobicistat
%K elvitegravir
%K pharmacokinetics
%K pregnancy
%~